Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EQUINOX: Idrabiotaparinux vs Idraparinux in DVT
NCT00311090Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2006
- Primary completion
- Jan 2008
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of idrabiotaparinux in deep vein thrombosis (DVT) (2 arms), sponsored by Sanofi. Primary endpoints: Idrabiotaparinux/Idraparinux Ratio for Pharmacodynamic Exposure Parameters at Day 183 and Decrease in Anti-Xa Activity at Day 188. Started Apr 2006; status: completed.
02
Drugs
idrabiotaparinux
03
Conditions
deep vein thrombosis (DVT)
Beyond the preview
Go deeper on NCT00311090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00311090.